From the Channing Laboratory and
Division of
Infectious Diseases, Brigham and Women's Hospital, and
¶ Department of Microbiology and Molecular Genetics, Harvard
Medical School, Boston, Massachusetts 02115
Received for publication, June 28, 2000, and in revised form, September 10, 2000
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Several species of streptococci produce
extracellular polysaccharides in the form of secreted
exopolysaccharides or cell-associated capsules. Although the biological
properties and repeating unit structures of these polysaccharides are
diverse, sequence analysis of the genes required for their production
has revealed a surprising degree of conservation among five genes found
in the capsule gene cluster of each of several polysaccharide-producing
streptococci. To determine the function of these conserved genes, we
characterized a series of isogenic mutants derived from a wild-type
strain of type Ia group B Streptococcus by selectively
inactivating each gene. Inactivation of cpsIaE resulted in
an acapsular phenotype, consistent with previous work that identified
the cpsIaE product as the glycosyltransferase that
initiates synthesis of the polysaccharide repeating unit. Mutants in
cpsIaA, cpsIaB, cpsIaC, or
cpsIaD produced type Ia capsular polysaccharide, but in
reduced amounts compared with the wild type. Analysis of the mutant
polysaccharides and of capsule gene transcription in the mutant strains
provided evidence that cpsIaA encodes a transcriptional
activator that regulates expression of the capsule gene operon. Mutants
in cpsIaC or cpsIaD produced polysaccharide of
reduced molecular size but with an identical repeating unit structure
as the wild-type strain. We conclude that CpsA to -D are not required
for polysaccharide repeating unit biosynthesis but rather that they
direct the coordinated polymerization and export of high molecular
weight polysaccharide.
Several species of streptococci of medical and industrial
importance produce extracellular polysaccharides in the form of secreted exopolysaccharides or as cell-associated polysaccharide capsules. For pathogenic streptococci such as Streptococcus
pneumoniae and group B Streptococcus
(Streptococcus agalactiae or
GBS),1 the capsular
polysaccharide is a major virulence factor as well as a target for
protective immunity. Therefore, considerable attention has focused on
characterization of the molecular basis for polysaccharide production.
Beginning with the identification of the GBS type III capsule locus
over a decade ago (1), rapid progress has been made in uncovering the
genetic and biochemical basis for capsular polysaccharide expression in
the streptococci.
A common theme that has emerged among encapsulated Gram-negative
bacteria is that the capsule locus consists of a region encoding polysaccharide-specific genes required for polysaccharide repeating unit biosynthesis flanked by groups of genes involved in broadly conserved functions such as transport and regulation (2). Similarly, the capsule gene region of several polysaccharide-producing
streptococci consists of a group of polysaccharide-specific genes
encoding glycosyltransferases and polymerases as well as an adjacent
group of genes that is conserved among several species (3-6). The
functions of these conserved genes are unproven, but they are thought
to direct such common processes as repeating unit polymerization, transport, and regulation.
For GBS, nine different capsule serotypes have been described, and the
repeating unit structure of each has been determined (7-15). The type
Ia polysaccharide has a linear backbone made up of disaccharide repeat
units of
Upstream of cpsIaE are cpsIaA to
cpsIaD, genes that, together with cpsE, are well
conserved among the GBS capsule serotypes and among other
polysaccharide-producing streptococci such as S. thermophilus, S. pneumoniae, and S. suis
(Fig. 1), (4, 6, 16, 17). Homologs of
some of these genes are found also in the polysaccharide synthesis gene
clusters of other Gram-positive bacteria including Lactococcus
lactis and Staphylococcus aureus (18, 19). Tentative
functions have been suggested for cpsA to -D on
the basis of sequence similarity to genes in other species. A homolog
of the gene product encoded by cpsA, LytR, appears to regulate transcription of the structural genes of the
N-acetylmuramoyl-L-alanine amidase operon of
Bacillus subtilis (20). Proteins encoded by homologs of
cpsC and cpsD have been implicated in chain
length regulation of exopolysaccharide production in R. meliloti and lipopolysaccharide biosynthesis in Escherichia
coli (21, 22). A recent report by Morona et al. (23)
provided the first experimental evidence for the function of these four
conserved genes in polysaccharide-producing streptococci. Nonpolar
deletion mutations in any of the four genes reduced capsule production
by S. pneumoniae type 19f (23). CpsD was shown to be an
autophosphorylating protein-tyrosine kinase, similar to Wzc in E. coli, whose phosphorylation state influences polysaccharide
production (23). CpsC and -B appeared to influence phosphorylation and
dephosphorylation, respectively, of CpsD (23).
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
4)-
-D-Glcp-(1
4)-
-D-Galp-(1
with a trisaccharide side chain of
-D-NeupNAc-(2
3)-
-D-Galp-(1
4)-
-D-GlcpNAc-(1
linked to C3 of each
-D-galactose residue of the
backbone (8). The genetic locus for the synthesis of the type Ia GBS
capsule includes at least 16 open reading frames and is predicted to
contain two promoters (6). One promoter region is upstream of the first gene, cpsIaA (Fig. 1) (6). RT-PCR and primer extension
analysis suggested that a second promoter lies between
cpsIaD and cpsIaE (Fig. 1) (6). On the basis of
DNA sequence analysis and enzymatic assays of gene products in E. coli, functions have been assigned to many of the genes in the
cluster. cpsIaE, cpsIaG, cpsIaI, and cpsIaJ appear to encode all of the specific
glycosyltransferases required for biosynthesis of the type Ia
polysaccharide repeating unit with the exception of the
sialyltransferase, which has not yet been identified (6).
cpsIaE encodes the glycosyltransferase thought to initiate
biosynthesis of the polysaccharide repeating unit. neuA to
-D encode enzymes involved in sialic acid synthesis and
activation (6).
View larger version (10K):
[in a new window]
Fig. 1.
Conserved genes in the polysaccharide
synthesis locus of GBS (S. agalactiae) and other
streptococci (accession numbers AB028896.1, AF053348, and
AF094575). Numbers in parenthesis represent the percentage
similarity in predicted amino acid sequence compared with the
corresponding protein in type Ia GBS.
In this report, we describe the construction and characterization of
nonpolar deletion mutants in cpsIaA, cpsIaB,
cpsIaC, cpsIaD, and cpsIaE in type Ia
GBS. Analysis of the mutants and their purified capsular
polysaccharides provided experimental evidence for the involvement of
each gene in polysaccharide elongation, export, or regulation. In
addition, our data specifically identify CpsIaA as an activator of
capsule gene transcription and demonstrate that CpsIaC and CpsIaD both
control polysaccharide chain length.
![]() |
EXPERIMENTAL PROCEDURES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Bacterial Strains, Plasmids, and Growth Conditions--
Type Ia
GBS strain 515 was used as the parent strain for all mutants
constructed in this report (24). GBS was grown in liquid culture in
Todd-Hewitt broth (Difco) supplemented with yeast extract to 0.5%
(w/v) (Todd-Hewitt-yeast), on trypticase soy agar supplemented with 5%
sheep blood (Becton-Dickinson, Cockeysville, MD), or on Todd-Hewitt-yeast agar plates supplemented with antibiotics and 5%
defibrinated sheep blood (PML Microbiologicals, Tulatin, OR). For
continuous culture experiments, GBS was grown in a chemically defined
medium as described (25) except that glycine was not added, NaOH was
added at 0.4 g/liter, and 7 g/liter of Casitone (Difco) was substituted
for the amino acid mix. E. coli strain DH5 MCR (Life
Technologies, Inc.) was used for cloning and was grown in Luria-Bertani
medium or on Luria-Bertani agar. When appropriate, the medium was
supplemented with ampicillin at 100 µg/ml or with erythromycin (erm)
at 1 µg/ml for GBS or 250 µg/ml for E. coli. GBS was
grown either without shaking in liquid culture or in continuous culture
as described previously (25). E. coli was grown with shaking
at 37 °C. Plasmid pGEM-T (Promega, Madison, WI) is an E. coli vector used for the direct cloning of PCR products; pJRS233 is a temperature-sensitive E. coli/Gram-positive shuttle
vector (26). pWKS30 is a low copy number cloning vector encoding
ampicillin resistance (27).
DNA Isolation and Manipulations-- Plasmid DNA was isolated using either the Qiagen midiprep or miniprep kit (Qiagen, Valencia, CA) according to the manufacturer's recommendations. GBS chromosomal DNA was prepared as described (28). Restriction endonuclease digestions, DNA ligations, transformation of CaCl2-competent E. coli, agarose gel electrophoresis, and Southern hybridizations (ECL; Amersham Pharmacia Biotech) were performed using standard techniques (29). GBS electrocompetent cells were prepared as described (30) and transformed by electroporation using a Bio-Rad Gene Pulser II (Bio-Rad) as described (31).
Construction of cps Nonpolar Deletion Mutants-- For cpsIaA deletion construction, primers 275 and 276 (Table I) were used to amplify by PCR the first 126 bp of cpsIaA and 736 bp of adjacent upstream flanking sequence using GBS strain 515 chromosomal DNA as template. Primers 267 and 277 (Table I) were used to amplify the last 104 bp of cpsIaA and 1535 bp of downstream flanking DNA. Primer 277 contains 18 bp of DNA that is complementary to the sequence in primer 276. The two gel-purified PCR products containing complementary ends were mixed and amplified with primers 275 and 267 to create a 1100-bp internal deletion of cpsIaA by overlap PCR (32, 33). The resultant 2500-bp PCR fragment was digested with HindIII and ligated into HindIII-digested pJRS233.
|
A deletion mutant in cpsIaB was constructed as above, except that primer pairs 280 and 314 (Table I) were used to amplify the 5'-terminal 100 and 900 bp of adjacent upstream flanking DNA. Primers 284-315 (Table I) were used to amplify the 3'-terminal 100 and 900 bp of downstream flanking DNA, with primer 284 containing 26 bp of DNA that is complementary to primer 280. The cpsIaB amplification products were used in an overlap PCR with primers 314 and 315 to introduce a 500-bp deletion of cpsIaB. The 2200-bp overlap PCR product was digested with BamHI and PstI and ligated into BamHI/PstI-digested pJRS233.
To construct a cpsIaC deletion, primers 252 and 253 (Table I) were used to amplify a 1900-bp fragment containing the coding sequences for cpsIaC and 600 bp of upstream and downstream flanking DNA. The cpsIaC amplification product was ligated into pGEM-T, and an internal 200-bp fragment of cpsIaC was released by digesting with XbaI and EcoRV. The 5' overhangs were filled in using the large fragment of DNA polymerase 1 (Klenow) to create blunt ends. The plasmid was then religated to create an internal cpsIaC deletion. The 1600-bp fragment containing the cpsIaC deletion and flanking sequences was released from pGEM-T by digestion with BamHI and KpnI and ligated into BamHI/KpnI-digested pJRS233.
An internal deletion of cpsIaD was constructed as described for cpsIaA and cpsIaB except that primer pairs 254 and 273 and 257 and 274 (Table I) were used to amplify the flanking PCR products, and primers 254 and 257 were used for the overlap extension reaction. The overlap amplification product was digested with BamHI and KpnI and ligated into BamHI/KpnI-digested pJRS233.
For construction of an internal deletion of cpsIaE, primers
119 and 121(Table I) were used to amplify a 1900-bp fragment containing
the complete coding sequence of cpsIaE. The amplification product was digested with BglII and EcoRI to
remove all but the first 100 bp of cpsE and 600 bp of
upstream flanking DNA. This fragment was ligated into
BamHI/EcoRI-digested pWKS30 to produce pWKS30-cpsIaE containing a BamHI site at the
5'-end of the insert and an EcoRI site at the 3'-end of the
insert. Primers 190 and 191 (Table I) were used to amplify a 670-bp
fragment containing the last 570 bp of cpsIaE and 100 bp of
downstream flanking DNA. The amplification product of the 3'-end of
cpsIaE was digested with EcoRI and
HindIII and ligated into
EcoRI/HindIII-digested pWKS30-cpsIaE
to create a 360-bp internal deletion of cpsIaE. The fragment
including the cpsIaE deletion and flanking DNA was released
from pWKS30-cpsIaE by digestion with HindIII
and XbaI and was ligated into
HindIII/XbaI-digested pJRS233.
Gene Replacement Mutagenesis in GBS Strain 515--
Each of the
cps deletion constructs in the temperature-sensitive shuttle
vector pJRS233 was introduced into GBS strain 515 by electroporation,
and transformants were selected by growth at 30 °C in the presence
of erm. A single erm-resistant colony was used to inoculate a liquid
culture supplemented with erm. After overnight incubation at 30 °C,
the culture was diluted 10-fold with fresh broth containing erm and
incubated at 37 °C to select organisms in which the recombinant
plasmid had integrated in the cps locus of the GBS
chromosome by homologous recombination (Fig. 2). Dilutions of each culture were plated
on medium containing erm and incubated overnight; erm-resistant
colonies representing plasmid integrants were serially passaged twice
on solid medium at 37 °C. Integrant strains were serially passaged
at least five times in broth at 30 °C in the absence of erm;
excision of the plasmid from the chromosome via a second recombination
event either completed the allelic exchange or reconstituted the
wild-type genotype (Fig. 2). erm-sensitive colonies were screened for
the expected deletion mutation by PCR amplification using primer pairs that flank the target gene. Candidate deletion mutants were
characterized by Southern hybridization analysis of
HindIII-digested chromosomal DNA probed with the target gene
to confirm the expected internal deletion and with pJRS233 to confirm
loss of plasmid sequences from the mutant strain.
|
Immunologic Techniques-- For immunoblot analysis to assess type Ia polysaccharide production by potential cps deletion mutants, bacterial colonies were lifted onto nitrocellulose filters (Schleicher and Schuell), fixed in 70% ethanol for 5 min, and blocked with 5% skim milk in PBS containing 0.5% Tween 20 (Sigma) (PBS-Tween). Filters were washed with PBS-Tween between subsequent steps. Type Ia polysaccharide was detected using rabbit antiserum evoked by immunization with GBS type Ia polysaccharide conjugated to tetanus toxoid (Ia-TT antiserum) (24). This antiserum has been shown to be highly specific for type Ia GBS polysaccharide; it binds less well to the closely related type Ib polysaccharide but does not recognize type II or III GBS polysaccharides (24). Filters were incubated with Ia-TT antiserum diluted 1:3000 in PBS-Tween, followed by incubation with alkaline phosphatase-conjugated goat anti-rabbit IgG (ICN/Cappel, Costa Mesa, CA) diluted 1:1000 in PBS-Tween and 5-bromo-4-chloroindolyl-3-phosphate/ nitro blue tetrazolium substrate (Kirkegaard and Perry Laboratories, Gaithersburg, MD).
Competition ELISA was used to quantify type Ia capsular polysaccharide production by mutant strains. Serial dilutions of a mutanolysin extract (see below) of the test strain were mixed with Ia-TT antiserum (final dilution, 1:500,000) in microtiter wells coated with type Ia polysaccharide conjugated to human serum albumin. The remainder of the ELISA procedure was performed as described (34).
Type Ia polysaccharide and group B carbohydrate were detected in chromatography column fractions by double diffusion in agarose using Ia-TT antiserum and antisera to group B carbohydrate, respectively (35).
Preparation of Mutanolysin Extracts for Measurement of Surface-expressed Capsular Polysaccharide-- For measurement of cell-associated capsular polysaccharide produced by mutant strains, cells from a 100-ml overnight culture were washed in PBS and resuspended in 1 ml of protoplast buffer (30 mM NaHPO4, 40% sucrose (w/v), 10 mM MgCl2). Capsular polysaccharide was released from the cells by the addition of 1000 units of mutanolysin (Sigma). After 6 h of incubation at 37 °C, the protoplasts were removed by centrifugation at 3800 × g for 15 min. The amount of type Ia polysaccharide in the extract was determined using serial dilutions of the extract in a competition ELISA by comparison with a standard curve generated with purified type Ia capsular polysaccharide as described above.
Purification of Capsular Polysaccharide-- GBS wild-type strain 515 and mutant strains were grown in continuous culture as described (25). Bacterial cells were collected by centrifugation and washed with PBS, and the capsular polysaccharide was extracted from the cell pellets by shaking at 37 °C for 30 h with 0.25 N NaOH. Cell extracts were neutralized with HCl and clarified by centrifugation at 13,000 × g for 20 min. After dialysis, extracts were filtered sterile and lyophilized. Each sample was resuspended in 30 ml of 69 mM sodium borate, and the pH was raised to greater than 10 by the addition of 10 N NaOH. The polysaccharide was reacetylated by the addition of 1.8 ml of acetic anhydride at room temperature; pH was maintained at 10 or higher by the addition of 10 N NaOH. The mixture was stirred for 2 h, neutralized with HCl, dialyzed, filtered sterile, and lyophilized. Samples were dissolved in 20 ml of enzyme treatment buffer (10 mM Tris, pH 7.4, 10 mM CaCl2, 10 mM MgCl2) and incubated with DNase (1 mg) and RNase (5 mg) overnight at 37 °C. Samples were incubated with Pronase (2 mg) at 37 °C overnight, dialyzed, and lyophilized. Polysaccharide samples were dissolved in water at a concentration of 25 mg/ml and purified by gel filtration chromatography on a 5 × 100-cm column of Sephacryl S-200 (Amersham Pharmacia Biotech) with PBS as eluant. Column fractions were screened for the presence of type Ia capsular polysaccharide and for group B carbohydrate by Ouchterlony immunodiffusion as described above. If necessary, capsular polysaccharides were further purified by anion exchange chromatography on a column of DEAE-Sepharose (Amersham Pharmacia Biotech) equilibrated with 10 mM Tris, pH 7.5, and eluted with a 0-0.4 M NaCl gradient. Fractions were assayed as above.
Carbohydrate Analysis-- Samples were analyzed by high performance anion exchange chromatography using a gradient system (Dionex, Sunnyvale, CA) equipped with a pulsed amperometric detector (model PAD2) and a pellicular anion exchange column (PA-1; 4 × 250 mm). The detector sensitivity was set at 300 nA with a 0.05-V applied pulse potential. Samples were hydrolyzed with 0.5 M trifluoroacetic acid at 100 °C for 18 h for analysis of neutral and amino sugars. After the removal of trifluoroacetic acid by repeated evaporation in water, hydrolyzed samples were applied through a microinjection valve with a 50-µl loop. Neutral sugars were eluted with 20 mM sodium hydroxide at a flow rate of 1 ml/min. For detection of sialic acid, samples were treated with 6% acetic acid at 80 °C for 2 h. After removal of acetic acid by repeated evaporation in water, samples were dissolved in water, applied to the column as above, and eluted with 90 mM sodium acetate and 100 mM sodium hydroxide.
NMR Analysis-- Purified polysaccharide samples were dissolved in deuterium oxide at a concentration of 3 mg/ml and subjected to 1H NMR analysis on a Varian Unity 500 spectrometer (Varian Medical Systems, Palo Alto, CA) with a frequency of 500 MHz. Spectra generated by each sample at 60 °C were recorded with chemical shifts referenced relative to water resonance at 4.42 ppm. Water resonance was calibrated externally using dioctyl sodium sulfosuccinate as the standard.
Molecular Size Analysis of Capsular Polysaccharides-- Purified capsular polysaccharide was analyzed by gel filtration FPLC on a column of Superose 12 HR 10/30 (Amersham Pharmacia Biotech) equilibrated in PBS. Samples were eluted in the same buffer at a flow rate of 0.5 ml/min with continuous monitoring of refractive index. Elution of capsular polysaccharide in fractions corresponding to the refractive index peaks was confirmed by competition ELISA. Molecular size of each polysaccharide was calculated on the basis of Kav by comparison with a calibration curve generated using dextran standards.
RNA Isolation and Analysis--
Total cellular RNA was isolated
from GBS grown in liquid culture to A600 = 0.4 using the RNeasy RNA isolation kit (Qiagen) according to the
manufacturer's recommendations except that GBS cells were lysed by
shearing with glass beads on a vortex mixer (36). Total RNA was eluted
in 40 µl of RNase-free water and treated with DNase I (Life
Technologies) as recommended by the manufacturer. For RT-PCR, 20 ng of
RNA was used for cDNA synthesis and subsequent PCR amplification
using the Access RT-PCR kit (Promega) according to the manufacturer's
recommendations. The amplification product was fractionated on 0.7%
agarose and stained with ethidium bromide, and the image was digitally
captured using the Foto/Analyst Archiver (Fotodyne, Hartland, WI).
RT-PCR amplification products were quantified by densitometric analysis
using NIH Image version 1.62. Values were normalized as a ratio of
target gene RNA to GBS recA RNA.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Construction and Characterization of GBS Mutant Strains--
The
first five genes of the GBS type Ia capsule synthesis locus
(cpsIaABCDE) are proposed to be expressed as part of a
single transcriptional unit (6). Accordingly, to investigate the
function of these genes, we introduced a nonpolar deletion mutation in each open reading frame. This strategy permitted the assessment of each
mutant phenotype independent of potential polar effects on expression
of downstream genes. DNA sequences representing the 5'- and 3'-ends of
the target gene plus flanking sequences were amplified by PCR and then
fused to create an internal deletion encompassing most of the coding
sequence of each gene (32, 33). Each internally deleted gene was cloned
into the temperature-sensitive shuttle vector pJRS233 (26), and the
recombinant plasmid was introduced into the GBS type Ia strain 515 by
electroporation. Allelic exchange of the internally deleted gene for
the chromosomal wild-type copy was achieved by a two-step process in
which the plasmid carrying the mutant allele was first integrated into
the cps operon by homologous recombination (Fig. 2). Plasmid
excision from the chromosome via a second recombination event at the
permissive temperature (30 °C) either completed the allelic exchange
or reconstituted the wild-type genotype (Fig. 2).
Erythromycin-sensitive colonies were screened by PCR with primers
specific to the target gene to confirm the expected internal deletion.
The genotype of each mutant was further confirmed by Southern
hybridization analysis of HindIII-digested chromosomal DNA
probed with the target gene. In addition, the digested chromosomal DNA
was probed with pJRS233 to confirm that the plasmid had been lost from
each mutant strain. The capsule phenotype that resulted from
inactivation of each gene was determined by colony immunoblot analysis.
Of the five mutant strains (designated 515-cpsIaA,
515-cpsIaB
, etc.), only 515-cpsIaE
was
completely devoid of type Ia capsular polysaccharide by immunoblot
analysis (Fig. 3). Previous studies have
indicated that cpsIaE encodes a glycosyltransferase
responsible for the addition of a monosaccharide to a lipid
intermediate to initiate assembly of the oligosaccharide repeating unit
(6, 37, 38). In type III GBS, inactivation of cpsD, a
cpsIaE homolog, by a transposon insertion resulted in
reduced galactosyltransferase activity, although polar effects on
downstream genes could have contributed to this phenotype (37).
Expression in E. coli of cpsIaE from type Ia GBS
or of the homologous cps14E from type 14 S. pneumoniae was associated with glucosyltransferase activity (6,
39). Regardless of whether UDP-glucose or UDP-galactose is the actual
substrate for the enzyme, the acapsular phenotype generated in the
present investigation by inactivation of cpsIaE is
consistent with the proposed role of CpsIaE as the initiating enzyme in
polysaccharide repeating unit biosynthesis. Unlike the cpsIaE deletion mutant, mutants harboring deletions in
cpsIaA, cpsIaB, cpsIaC, or
cpsIaD were all positive for cell-associated type Ia
capsular polysaccharide by colony immunoblot analysis (Fig. 3). These
results suggested that CpsA to -D are not absolutely required for
repeating unit synthesis but rather that they direct polymerization,
export, and/or regulation. Therefore, a detailed examination was
undertaken of the effects of each mutation on polysaccharide structure,
quantity, cellular location, and chain length.
|
Analysis of 515-cpsIaA--
Colony immunoblot screening of
515-cpsIaA
was positive, a result that indicated
production by the mutant strain of cell-associated polysaccharide
recognized by type-specific antiserum (Fig. 3). The amount of
polysaccharide produced by the mutant strain relative to that produced
by the wild-type parent strain 515 was quantified using an ELISA
inhibition assay: strain 515-cpsIaA
produced 24% as much
cell-associated polysaccharide as wild-type strain 515 (Fig.
4). Assays of culture supernatants and of
cell lysates showed no increase in polysaccharide released into the
growth medium nor in intracellular polysaccharide in the mutant
relative to the parent strain (data not shown). These results indicated
that inactivation of CpsIaA reduced cell surface expression of type Ia
capsular polysaccharide but was not associated either with intracellular accumulation of polysaccharide or with increased release
of polysaccharide from the cell surface.
|
The apparent reduction in cell-associated polysaccharide observed in
515-cpsIaA might have been due to one or more different effects on polysaccharide expression such as an altered polysaccharide structure resulting in reduced reactivity with type-specific antiserum, production of fewer polysaccharide molecules at the cell surface, or
reduced polysaccharide chain length. To distinguish among these possibilities, capsular polysaccharide was purified from a large scale
culture of 515-cpsIaA
grown under controlled conditions. Polysaccharide was extracted from 515-cpsIaA
(or from
wild-type strain 515 for comparison) and purified by sequential
enzymatic treatment followed by gel filtration chromatography.
Component sugar analysis of the purified polysaccharide by high
performance anion exchange chromatography with a pulsed amperometric
detector demonstrated the presence of N-acetylglucosamine,
galactose, glucose, and N-acetylneuraminic acid (sialic
acid) in a molar ratio of 0.9:2.0:1.4:0.7, an analysis nearly identical
to that of polysaccharide purified from parent strain 515 and
consistent with the previously reported structure of the type Ia GBS
polysaccharide (Fig. 4) (8).
The 1H NMR spectra of the purified 515-cpsIaA
polysaccharide and the parent strain 515 polysaccharide exhibited
resonance peaks with identical chemical shifts for each of four
anomeric protons between 4.5 and 5.1 ppm, evidence that the composition and linkage pattern of the hexoses are the same (Fig. 4). Sialic acid
was similarly detected in both samples as evidenced by its characteristic H-3 signals at 1.78 (due to the axial proton) and 2.75 ppm (due to the equatorial proton). Both the 515-cpsIaA
polysaccharide and the parent strain 515 polysaccharide were fully N-acetylated, as indicated by the relative intensity of the
signal at 2.04 ppm. The cluster of signals between 3.3 and 4.2 ppm
arising from the nonanomeric sugar ring protons showed a virtually
identical pattern in the two spectra except for minor discrepancies
attributable to small amounts of impurities in the samples. Thus,
results of both component sugar analysis and 1H NMR
spectroscopy provided strong evidence that the repeating unit structure
of the 515-cpsIaA
polysaccharide is identical to that of
parent strain 515. Comparison of NMR spectra of these samples with that
of polysaccharide from strain 090, the prototype strain from which the
type Ia polysaccharide structure was determined, indicated identical
repeating unit structures for the three polysaccharides (8).
To determine whether the apparent reduction in capsule production by
515-cpsIaA might be due to altered polysaccharide chain length, the molecular size of the purified mutant polysaccharide was
assessed by gel filtration FPLC. The 515-cpsIaA
polysaccharide eluted with a Kav of 0.20 compared with a Kav of 0.23 for polysaccharide purified from parent strain 515 (Fig. 5).
These Kav values correspond to
Mr values of 100,000 and 90,000, respectively,
using a calibration curve constructed with dextran standards. Results
of this analysis indicated that inactivation of CpsIaA had no
significant effect on polysaccharide chain length. Since repeating unit
structure and chain length of the 515-cpsIaA
polysaccharide were both essentially identical to the wild-type
polysaccharide, it appeared that inactivation of CpsIaA resulted in
expression of fewer molecules of type Ia polysaccharide at the cell
surface relative to the wild-type strain.
|
CpsIaA has 44% similarity to LytR, a protein in Bacillus
subtilis that is thought to act as a transcriptional regulator and has been suggested to perform the same role in GBS capsule expression (40). Disruption of lytR resulted in a 4-fold increase in
transcription of lytABC, supporting a role for LytR as an
attenuator of lyt operon transcription (20). A possible
function of CpsIaA as a regulator of GBS capsule gene transcription was
investigated by measuring transcription of the cps operon in
515-cpsIaA and in wild-type strain 515. RT-PCR using
primers for cpsIaD revealed 2-3-fold more transcripts in
strain 515 than in 515-cpsIaA
(Fig. 6). Reduced transcription of the
cps operon in 515-cpsIaA
suggests that CpsIaA
regulates cps gene expression, but, in contrast to LytR,
CpsIaA appears to function as an activator of target gene transcription. The reduced amount of capsular polysaccharide produced by 515-cpsIaA
is an expected consequence of reduced
cps operon expression.
|
Analysis of 515-cpsIaB--
By immunoblot analysis,
515-cpsIaB
appeared to be positive for production of
immunoreactive type Ia polysaccharide by comparison with a control type
III strain or with the capsule-negative mutant 515-cpsIaE
(Fig. 3). However, the signal from 515-cpsIaB
was weaker
than that from wild-type strain 515 or from 515-cpsIaA
, 515-cpsIaC
, or 515-cpsIaD
. Quantitative
ELISA inhibition analysis on capsular polysaccharide extracts
demonstrated that 515-cpsIaB
produced ~3% of the
quantity of cell-associated type Ia polysaccharide produced by parent
strain 515 (Fig. 4). No intracellular accumulation of polysaccharide
was detected in 515-cpsIaB
; nor was polysaccharide detected in culture supernatants (data not shown). The very small quantity of polysaccharide produced by 515-cpsIaB
precluded further analysis of the mutant polysaccharide.
In experiments like those described above for 515-cpsIaA,
we assessed whether inactivation of CpsIaB affected transcription of
the cps operon. Using cpsIaD as a target, we
found no reduction in cps gene transcripts by RT-PCR (Fig.
6B). This result provides evidence that the reduced
production of capsular polysaccharide in 515-cpsIaB
was
not attributable to an effect on cps gene expression.
Analysis of 515-cpsIaC and 515-cpsIaD
--
Immunoblot
analysis indicated that both 515-cpsIaC
and
515-cpsIaD
produced immunoreactive capsular
polysaccharide (Fig. 3). Quantitative analysis of cell-associated
capsule by ELISA inhibition indicated that 515-cpsIaC
and
515-cpsIaD
produced 6 and 9%, respectively, of the
amount produced by parent strain 515. Capsular polysaccharide was
purified from large scale cultures of both 515-cpsIaC
and
515-cpsIaD
. Component sugar analysis and
1H-NMR of the purified polysaccharides indicated that the
repeating unit structure of each was identical to that of the type Ia
parent strain 515 (Fig. 4).
Several reports have noted the similarity of CpsC and CpsD in GBS and
in other streptococci to proteins implicated in the polymerization and
export of polysaccharides in Gram-negative bacteria, including ExoP of
R. meliloti and the Wzz and Wzc proteins of
enterobacteriaeceae (4, 6, 16, 23). Since these proteins in
Gram-negative bacteria appear to affect polysaccharide chain length, we
investigated whether inactivation of CpsIaC or CpsIaD affected the
molecular size of the GBS type Ia polysaccharide. Analysis of the
polysaccharides purified from 515-cpsIaC and 515-cpsIaD
by gel filtration FPLC revealed that both were
reduced in size compared with polysaccharide from parent strain 515. The 515-cpsIaC
polysaccharide had a
Kav of 0.33 (Mr of
41,000), and the 515-cpsIaD
polysaccharide had a
Kav of 0.32 (Mr of
45,000), compared with a Kav of 0.23 (Mr of 90,000) for 515 polysaccharide (Fig. 5).
In addition, each of the two mutant polysaccharides eluted in a
narrower peak than did the wild-type, a result that implies a more
restricted range of molecular sizes among the polysaccharide chains
produced by the mutants compared with those of the wild-type or
515-cpsIaA
. Since the average chain length of
polysaccharide produced by 515-cpsIaC
and
515-cpsIaD
is about one-half of that produced by the
wild-type, it seems unlikely that reduced chain length alone accounts
for the >90% reduction in cell-associated polysaccharide measured by
immunoassay. Thus, inactivation of either CpsIaC or CpsIaD results in
reduced polysaccharide chain length and, probably, a reduction in the
number of polysaccharide molecules expressed on the bacterial surface.
Lack of Effect of CpsIaC or CpsIaD on cps Gene
Transcription--
To investigate whether the decrease in capsular
polysaccharide production by 515-cpsIaC and
515-cpsIaD
was due to an effect on cps gene
transcription, we assessed the abundance of cps gene transcripts by RT-PCR in the two mutant strains using primers specific
for cpsIaD. In contrast to the decrease in cps
transcripts detected in 515-cpsIaA
, in
515-cpsIaC
and 515-cpsIaD
we observed similar levels of cps gene transcription as in wild-type
strain 515 (Fig. 6B). Therefore, the reduced production of
capsular polysaccharide in 515-cpsIaC
and
515-cpsIaD
was not attributable to effects of either
mutation on cps gene expression.
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In this paper, we describe the effects in type Ia GBS of nonpolar,
inactivating mutations in each of five genes that are highly conserved
among polysaccharide-producing streptococci. Of the five genes
examined, only a disruption of cpsIaE resulted in an acapsular phenotype. The cpsIaE phenotype is consistent
with the proposed role of CpsE as a glycosyltransferase responsible for
attachment of the first sugar to a lipid carrier to initiate repeating
unit synthesis (6, 37, 38). The striking conservation of
cpsA-E among GBS of different serotypes and among
other species of streptococci has suggested that the products of these
genes have functions that are independent of the repeating unit
structure of the associated polysaccharide. Southern analysis using
gene-specific probes from type Ia GBS confirmed the presence of all
five genes in GBS strains of types Ia, Ib, II, III, IV, V, VI, and VII.
cpsA to -D, but not cpsE, were
detected also in GBS type VIII (data not shown). Like the other known
GBS capsule types, the repeating unit structure of the type VIII
polysaccharide includes glucose, galactose, and sialic acid; however,
type VIII differs in the presence of rhamnose as part the repeating
unit (11). The apparent absence of a gene closely related to
cpsIaE in type VIII GBS suggests the possibility that a
unique enzyme, perhaps with rhamnose as a substrate, initiates
repeating unit synthesis in this serotype.
CpsA is similar to LytR, which is suggested to down-regulate transcription of the lyt operon. On the basis of evidence from the present study, CpsIaA regulates cps gene expression, but in contrast to LytR, CpsIaA acts as an activator of capsule gene transcription. A mutant in cpsIaA produced type Ia capsular polysaccharide of similar Mr as the wild-type, but in reduced amounts, and inactivation of CpsIaA was associated with reduced expression of the type Ia capsule gene cluster. Several features differentiate LytR from CpsIaA and its homologs. Unlike LytR, the N-terminal portion of CpsIaA includes predicted membrane-spanning domains. Unlike lytR, cpsIaA is transcribed as part of a polycistronic message along with other genes of the type Ia capsule gene cluster, whereas transcription of lytR in B. subtilis is divergent from that of the operon it regulates. In addition, hydrophobic regions found in CpsIaA and its homologs in other streptococci do not correspond to homologous regions in LytR (20). These or other structural differences between the two proteins may account for the observation that CpsIaA appears to act as an activator while LytR attenuates gene expression.
A definitive role of CpsIaB in capsule expression has yet to be determined. In S. pneumoniae, inactivation of Cps19fB was associated with increased tyrosine phosphorylation of a 25-kDa protein tentatively identified as Cps19fD. This result suggested the possibility that Cps19fB functions as a phosphotyrosine-protein phosphatase that regulates capsule expression through its effect on the degree of phosphorylation of Cps19fD. In the present study, a GBS mutant in cpsIaB expressed low levels of cell-associated capsular polysaccharide. Whether this decrease in capsule expression is due to a reduction in number of polysaccharide molecules on the cell surface or reduced polysaccharide chain length or both was not determined because of the very small amount of capsular polysaccharide produced by the mutant strain. Inactivation of CpsIaB had no effect on expression of the cps gene cluster, so it seems unlikely that CpsIaB acts as a transcriptional regulator of capsule gene expression. The presence of CpsB in capsule biosynthetic loci of other species and the fact that inactivation of CpsB has a profound effect on capsule production suggest that it serves a critical function in transport or polymerization, but the exact nature of that function remains uncertain. It seems unlikely that the sole function of CpsB in GBS or S. pneumoniae is to regulate phosphorylation of CpsD, since the effect on capsule production associated with inactivation of CpsIaB was more pronounced than that of inactivating CpsIaD.
CpsIaC and CpsIaD are similar to amino- and C-terminal regions, respectively, of ExoP, a protein involved in R. meliloti exopolysaccharide biosynthesis (22). The amino-terminal portion of ExoP contains predicted membrane-spanning domains and is similar to proteins involved in polysaccharide polymerization or export (22). The C-terminal portion of the protein includes a putative ATP-binding domain (22). Although the similarity between CpsIaC and the N-terminal region of ExoP is quite low (<20%), CpsIaC does contain predicted membrane-spanning domains similar to ExoP. Disruption of cpsB in S. suis serotype 2 (73% similarity to cpsIaC) produced a capsule-negative phenotype by slide agglutination assay (5); however, the acapsular phenotype in the S. suis cpsB mutant may have been due to polar effects on downstream transcription caused by the insertion mutation. Morona et al. (23) showed that deletion mutants in S. pneumoniae cps19fC and cps19fD had a similar phenotype to the GBS cpsIaC and cpsIaD mutants characterized in our study insofar as the S. pneumoniae mutants also were positive for immunoreactive, cell-associated capsular polysaccharide but in reduced amounts compared with the parent strain. In S. pneumoniae, Cps19fD is an autophosphorylating protein-tyrosine kinase; point mutations in either the ATP-binding domain or the C-terminal (YGX)4 repeat domain eliminated tyrosine phosphorylation but had opposite effects on encapsulation. Cps19fC is also required for tyrosine phosphorylation of Cps19fD. The precise roles of ATP binding and of tyrosine phosphorylation of CpsD in regulating capsular polysaccharide production remain to be defined.
Effects on polysaccharide chain length of mutations in the pneumococcal
cpsC or cpsD have not been reported. In the
present investigation, the absence of intracellular polysaccharide in GBS 515-cpsIaC and 515-cpsIaD
suggests that
the processes of polysaccharide elongation and transport to the cell
surface are closely linked. The effect on polysaccharide chain length
observed in our study upon inactivation of either CpsIaC or CpsIaD
probably reflects reduced efficiency of the coupled
polymerization/export process. Our results in GBS, together with those
of Morona et al. (23) in S. pneumoniae, support a
model in which CpsB, CpsC, and CpsD function in a complex that directs
the coordinated polymerization and export to the cell surface of the
capsular polysaccharide.
Results of the present investigation provide evidence that each of the
proteins encoded by the conserved genes of the streptococcal polysaccharide gene cluster plays a critical role in the regulation, processing, and/or export of extracellular polysaccharide. Further characterization of the molecular details of the polysaccharide polymerization and export complex will provide a better understanding of an important aspect of the physiology of polysaccharide-producing streptococci and may define novel targets for directed drug design against encapsulated Gram-positive pathogens.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank Sarah Henderson for constructing
mutant strain 515-cpsIaE and Robin Ross, Ken Johnson, and
Barbara Reinap for assistance in purification and analysis of the
capsular polysaccharides.
![]() |
FOOTNOTES |
---|
* This work was supported in part by NIAID, National Institutes of Health (NIH), Grant AI42940.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ Supported in part by NIAID, NIH, Grant AI07061.
** To whom correspondence should be addressed: Channing Laboratory, 181 Longwood Ave., Boston, MA 02115. Tel.: 617-525-0086; Fax: 617-731-1541; E-mail: mwessels@channing.harvard.edu.
Published, JBC Papers in Press, October 10, 2000, DOI 10.1074/jbc.M005702200
![]() |
ABBREVIATIONS |
---|
The abbreviations used are: GBS, group B Streptococcus; erm, erythromycin; ELISA, enzyme-linked immunosorbent assay; FPLC, fast protein liquid chromatography; PBS, phosphate-buffered saline; PCR, polymerase chain reaction; RT-PCR, reverse transcriptase-PCR; bp, base pair(s).
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. | Rubens, C. E., Wessels, M. R., Heggen, L. M., and Kasper, D. L. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 7208-7212[Abstract] |
2. | Vimr, E., Steenbergen, S., and Cieslewicz, M. (1995) J. Ind. Microbiol. 15, 352-360[Medline] [Order article via Infotrieve] |
3. | Kolkman, M. A. B., van der Zeijst, B. A. M., and Nuijten, P. J. M. (1998) J. Biochem. (Tokyo) 123, 937-945[Abstract] |
4. | Stingele, F., Neeser, J.-R., and Mollet, B. (1996) J. Bacteriol. 178, 1680-1690[Abstract] |
5. |
Smith, H. E.,
Damman, M.,
Van Der Velde, J.,
Wagenaar, F.,
Wisselink, H. J.,
Stockhofe-Zurwieden, N.,
and Smits, M. A.
(1999)
Infect. Immun.
67,
1750-1756 |
6. |
Yamamoto, S.,
Miyake, K.,
Koike, Y.,
Watanabe, M.,
Machida, Y.,
Ohta, M.,
and Iijima, S.
(1999)
J. Bacteriol.
181,
5176-5184 |
7. | Jennings, H. J., Lugowski, C., and Kasper, D. L. (1981) Biochemistry 20, 4511-4518[Medline] [Order article via Infotrieve] |
8. | Jennings, H. J., Katzenellenbogen, E., Lugowski, C., and Kasper, D. L. (1983) Biochemistry 22, 1258-1264[Medline] [Order article via Infotrieve] |
9. | Jennings, H. J. (1990) Curr. Top. Microbiol. Immunol. 150, 97-127[Medline] [Order article via Infotrieve] |
10. | Kogan, G., Brisson, J.-R., Kasper, D. L., von Hunolstein, C., Orefici, G., and Jennings, H. J. (1995) Carbohydr. Res. 277, 1-9[CrossRef][Medline] [Order article via Infotrieve] |
11. |
Kogan, G.,
Uhrín, D.,
Brisson, J.-R.,
Paoletti, L. C.,
Blodgett, A. E.,
Kasper, D. L.,
and Jennings, H. J.
(1996)
J. Biol. Chem.
271,
8786-8790 |
12. | Di Fabio, J. L., Michon, F., Brisson, J.-R., and Jennings, H. J. (1989) Can. J. Chem. 67, 877-882 |
13. | von Hunolstein, C., Ascenzi, S. D., Wagner, B., Jelinkova, J., Alfarone, G., Recchia, S., Wagner, M., and Orefici, G. (1993) Infect. Immun. 61, 1272-1280[Abstract] |
14. |
Wessels, M. R.,
Pozsgay, V.,
Kasper, D. L.,
and Jennings, H. J.
(1987)
J. Biol. Chem.
262,
8262-8267 |
15. |
Wessels, M. R.,
DiFabio, J. L.,
Benedí, V.-J.,
Kasper, D. L.,
Michon, F.,
Brisson, J.-R.,
Jelinkova, J.,
and Jennings, H. J.
(1991)
J. Biol. Chem.
266,
6714-6719 |
16. | Guidolin, A., Morona, J. K., Morona, R., Hansman, D., and Paton, J. C. (1994) Infect. Immun. 62, 5384-5396[Abstract] |
17. | Garcia, E., Garcia, P., and Lopez, R. (1993) Mol. Gen. Genet. 239, 188-195[Medline] [Order article via Infotrieve] |
18. | Sau, S., Bhasin, N., Wann, E. R., Lee, J. C., Foster, T. J., and Lee, C. Y. (1997) Microbiology 143, 2395-2405[Abstract] |
19. | van Kranenburg, R., Marugg, J. D., van Swam, I. I., Willem, N. J., and de Vos, W. M. (1997) Mol. Microbiol. 24, 387-397[Medline] [Order article via Infotrieve] |
20. | Lazarevic, V., Margot, P., Soldo, B., and Karamata, D. (1992) J. Gen. Microbiol. 138, 1946-1961 |
21. | Batchelor, R. A., Haraguchi, G. E., Hull, R. A., and Hull, S. I. (1991) J. Bacteriol. 173, 5699-5704[Medline] [Order article via Infotrieve] |
22. | Becker, A., Niehaus, K., and Puhler, A. (1995) Mol. Microbiol. 16, 191-203[Medline] [Order article via Infotrieve] |
23. | Morona, J. D., Paton, J. C., Miller, D. C., and Morona, R. (2000) Mol. Microbiol. 35, 1431-1442[CrossRef][Medline] [Order article via Infotrieve] |
24. | Wessels, M. R., Paoletti, L. C., Rodewald, A. K., Michon, F., DiFabio, J., Jennings, H. J., and Kasper, D. L. (1993) Infect. Immun. 61, 4760-4766[Abstract] |
25. | Paoletti, L. C., Ross, R. A., and Johnson, K. D. (1996) J. Bacteriol. 64, 1220-1226 |
26. | Perez-Casal, J., Price, J. A., Maguin, E., and Scott, J. R. (1993) Mol. Microbiol. 8, 809-819[Medline] [Order article via Infotrieve] |
27. | Wang, R. F., and Kushner, S. R. (1991) Gene (Amst.) 100, 195-199[CrossRef][Medline] [Order article via Infotrieve] |
28. | O'Connor, S. P., and Cleary, P. P. (1987) J. Infect. Dis. 156, 495-504[Medline] [Order article via Infotrieve] |
29. | Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual , 2nd Ed. , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY |
30. | Caparon, M. G., and Scott, J. R. (1991) Methods Enzymol. 204, 556-586[Medline] [Order article via Infotrieve] |
31. | Albertí, S., Ashbaugh, C. D., and Wessels, M. R. (1998) Mol. Microbiol. 28, 343-353[CrossRef][Medline] [Order article via Infotrieve] |
32. | Ho, S. N., Hunt, H. D., Horton, R. M., Pullen, J. D., and Pease, L. R. (1989) Gene (Amst.) 77, 51-59[CrossRef][Medline] [Order article via Infotrieve] |
33. | Horton, R. M., Hunt, H. D., Ho, S. N., Pullen, J. D., and Pease, L. R. (1989) Gene (Amst.) 77, 61-68[CrossRef][Medline] [Order article via Infotrieve] |
34. | Guttormsen, H.-K., Baker, C. J., Edwards, M. S., Paoletti, L. C., and Kasper, D. L. (1996) J. Infect. Dis. 173, 142-150[Medline] [Order article via Infotrieve] |
35. | Ouchterlony, O. (1958) Prog. Allergy 5, 1-78 |
36. | Yim, H. H., and Rubens, C. E. (1997) BioTechniques 23, 229-231[Medline] [Order article via Infotrieve] |
37. | Rubens, C. E., Heggen, L. M., Haft, R. F., and Wessels, M. R. (1993) Mol. Microbiol. 8, 843-855[Medline] [Order article via Infotrieve] |
38. | Kolkman, M. A. B., Morrison, D. A., van der Zeijst, B. A. M., and Nuijten, P. J. M. (1996) J. Bacteriol. 178, 3736-3741[Abstract] |
39. |
Kolkman, M. A. B.,
van der Zeijst, B. A. M.,
and Nuijten, P. J. M.
(1997)
J. Biol. Chem.
272,
19502-19508 |
40. | Koskeniemi, S., Sellin, M., and Norgren, M. (1998) FEMS Immunol. Med. Microbiol. 21, 159-168[CrossRef][Medline] [Order article via Infotrieve] |